Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory multiple myeloma after four or more lines that included a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody.
LAMPGEN ANALYSIS
Why it matters
This accelerated approval added another BCMA-directed bispecific option after extensive prior therapy.
What research teams should watch
Verify line count and drug-class exposure, then plan step-up dosing and cytokine release syndrome monitoring.
PRIMARY RECORDS